Formulary Chapter 3: Respiratory system - Full Section
|
Notes:
Prescribing inhalers
• Prescribe by brand or branded-generic name to ensure patients receive the device they are used to. • Check licensed indication (differences among brands). • Be aware of differences in excipients among the different brands. |
Useful Links |
COPD Guidelines 2017- Pan Birmingham Respiratory Clinical Network |
Equality Analysis - Diagnosis and management of stable COPD- Pan Birmingham Respiratory Clinical Network guideline 2017 |
Appendix 4 Criteria for triple therapy and for triple inhaler use in COPD |
NICE TA10: Asthma inhaler devices (children under 5) |
UKMI Q&A: Nebuliser compatibilities |
Diagnosis and Management of Asthma in Adults Guideline - Pan Birmingham Respiratory Clinical Network (June 2019) |
NICE CG101: COPD guideline |
NICE TA38: Asthma inhaler devices (older children) |
Stoma Toolkit Adults |
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
03.01 |
Bronchodilators (0,0)
|
|

Asthma (0,0)
|
|

Chronic obstructive pulmonary disease (0,0)
|
|

Croup (0,0)
|
03.01.01 |
Adrenoceptor agonists (0,0)
|
03.01.01.01 |
Selective Beta2 agonists
(7,4)
|
|

Short-acting beta2 agonists (0,0)
|
|

Long-acting beta2 agonists (0,0)
|
03.01.01.02 |
Other adrenoceptor agonists
(0,2)
|
03.01.02 |
Antimuscarinic bronchodilators
(5,1)
|
|

Short Acting Anti-muscarinic Bronchodilators (0,0)
|
|

Long Acting Anti-muscarinic Bronchodilators (0,0)
|
03.01.03 |
Theophylline
(3,2)
|
03.01.04 |
Compound bronchodilator preparations
(4,2)
|
03.01.05 |
Peak flow meters, inhaler devices and nebulisers
(0,1)
|
|

Peak flow meters
(2,0)
|
|

Drug delivery devices
(2,0)
|
|

Nebuliser Diluent
(1,0)
|
03.02 |
Corticosteroids
(12,8)
|
03.02.01 |
Inhaled Corticosteroids (0,0)
|
03.02.02 |
Combination products (ICS+LABA) for asthma (0,0)
|
|

Low dose (0,0)
|
|

Moderate dose (0,0)
|
|

High dose (0,0)
|
03.02.03 |
Combination products (ICS+LABA) for COPD
(2,0)
|
03.03 |
Cromoglicate, related therapy and leukotriene receptor antagonists (0,0)
|
03.03.01 |
Cromoglicate and related therapy
(0,4)
|
|

Related therapy (0,0)
|
03.03.02 |
Leukotriene receptor antagonists
(1,1)
|
03.03.03 |
Phosphodiesterase type-4 inhibitors
(1,0)
|
03.04 |
Antihistamines, hyposensitisation, and allergic emergencies (0,0)
|
03.04.01 |
Antihistamines (0,0)
|
|

Non-sedating antihistamines
(3,6)
|
|

Sedating antihistamines
(4,3)
|
03.04.02 |
Allergen Immunotherapy
(4,0)
|
|

Omalizumab (0,0)
|
03.04.03 |
Allergic emergencies (0,0)
|
|

Anaphylaxis
(3,2)
|
|

Angioedema
(5,0)
|
|

Intramuscular adrenaline (epinephrine) (0,0)
|
|

Intravenous adrenaline (epinephrine)
(0,1)
|
|

Self-administration of adrenaline (epinephrine) (0,0)
|
03.05 |
Respiratory stimulants and pulmonary surfactants (0,0)
|
03.05.01 |
Respiratory stimulants
(2,0)
|
03.05.02 |
Pulmonary surfactants
(1,1)
|
03.06 |
Oxygen
(1,0)
|
|

Long-term oxygen therapy (0,0)
|
|

Short burst oxygen therpary (0,0)
|
|

Ambulatory oxygen therapy (0,0)
|
|

Oxygen therapy equipment (0,0)
|
|

Arrangements for supplying oxygen (0,0)
|
03.07 |
Mucolytics
(6,1)
|
|

Dornase alfa
(1,0)
|
|

Hypertonic Sodium Chloride
(2,3)
|
03.08 |
Aromatic inhalations
(0,3)
|
03.09 |
Cough preparations (0,0)
|
03.09.01 |
Cough suppressants
(1,6)
|
|

Palliative care
(1,1)
|
03.09.02 |
Expectorant and demulcent cough preparations
(2,1)
|
03.10 |
Systemic nasal decongestants
(1,0)
|
03.11 |
Antifibrotics
(2,0)
|
03.12 |
Other drugs for Interstitial lung disease (idiopathic pulmonary fibrosis)
(3,0)
|
03.13 |
Nebulised antibiotics for cystic fibrosis
(8,0)
|
03.14 |
Monoclonal Antibody
(4,0)
|
03.15 |
Cystic Fibrosis
(1,0)
|